Rectal Cancer Stages

Rectal cancer begins in the rectum, the final portion of the large intestine before the anus. Rectal cancer staging describes how deeply cancer has grown into or through the rectal wall and whether it has spread to lymph nodes or distant organs. Determining the stage is essential because this information guides decisions about surgery, radiation therapy, chemotherapy, immunotherapy and other treatments.

How rectal cancer is staged

Staging rectal cancer is a multistep process. The healthcare team must determine where the tumor is located within the rectum, how far it extends through the layers of the rectal wall, how close it is to the planned surgical margin and whether cancer is present in lymph nodes or distant organs.

The staging evaluation of rectal cancer may include:

• Colonoscopy with biopsy – During a colonoscopy, a physician will examine the lining of the rectum and the rest of the colon, record the tumor’s location and remove tissue for microscopic examination by a pathologist. A biopsy can confirm whether the lesion is cancerous and identify its histologic type, but a small biopsy usually cannot show the full depth of cancer invasion.
• Digital rectal examination and proctoscopy – A physical examination and a rigid or flexible scope can help define the tumor’s distance from the anal opening and its relationship to the sphincter muscles that control bowel movements. These details can affect whether sphincter-preserving surgery may be possible.
• High-resolution pelvic magnetic resonance imaging (MRI) – A rectal-protocol MRI can provide detailed images of the tumor, the rectal wall and surrounding tissues, regional lymph nodes and the mesorectal fascia, a tissue envelope around the rectum. These images can show whether the tumor extends beyond the muscular wall, approaches the mesorectal fascia or involves nearby organs, helping the healthcare team assess whether surgery is likely to achieve a clear circumferential resection margin.
• Endorectal ultrasound – A physician will place a small ultrasound probe in the rectum to generate images that can help distinguish tumors limited to the superficial layers from those that have entered the muscular wall. This procedure is used most often for early tumors and may be less useful if a tumor is large, causes significant narrowing of the rectum or is positioned beyond the probe’s reach.
• Computed tomography (CT) scans of the chest, abdomen and pelvis – These images can be used to evaluate common sites of distant rectal cancer spread, particularly the liver and lungs, as well as lymph nodes and other structures. CT is important for determining the M category but provides less detail than a rectal-protocol MRI for assessing the layers of the rectal wall.
• Positron emission tomography (PET)-CT – In select situations, PET-CT may be used if standard imaging shows a finding that remains unclear or when identifying otherwise unsuspected metastatic disease would change the treatment plan. It is not necessary for the routine staging of every rectal cancer.
• Laboratory and molecular testing – A baseline carcinoembryonic antigen (CEA) blood test may help assess the prognosis and later treatment response, although it does not determine the stage of rectal cancer on its own. Tumor testing for mismatch repair (MMR) proteins or microsatellite instability (MSI), along with broader biomarker testing when appropriate, can identify treatment options and a possible inherited cancer syndrome.
• Surgical pathology – If surgery is performed, a pathologist will examine the rectal tumor, margins, surrounding mesorectal tissue and removed lymph nodes. This evaluation can establish the pathological stage and identify additional features that help estimate recurrence risk.

"No cancer journey is linear, and mine was no exception. I stumbled across a few ‘humble humps’ along the way, which reminded me that even though things seem to be going well, it is still cancer, and there is no rulebook."

Karen, Rectal Cancer Survivor

 

Request an Appointment

Understanding the TNM categories

The AJCC TNM system describes three components of rectal cancer:

• T (tumor) – T describes the deepest layer or nearby structure reached by the primary tumor. Tis, or carcinoma in situ, is confined to the innermost lining; T1 reaches the submucosa; T2 reaches the muscularis propria, the thick muscle layer of the rectal wall; T3 extends through that muscle into surrounding tissue; and T4 reaches the surface of the peritoneum or invades another organ or structure.
• N (nodes) –  N describes cancer in regional lymph nodes or tumor deposits in nearby tissue. N0 means no regional lymph node involvement, while N1 and N2 reflect the number and pattern of involved nodes or deposits.
• M (metastasis) –  M describes distant spread. M0 means no distant metastasis has been found, while M1 indicates spread to a distant organ, distant lymph nodes or the peritoneum, the lining of the abdominal cavity.

The TNM findings are combined to assign an overall stage ranging from 0 to 4. Some stages are divided into subcategories, such as 2A, 2B and 2C, to describe the extent of the cancer more precisely.

Rectal cancer stages

Each rectal cancer stage reflects a specific pattern of tumor growth, lymph node involvement and distant spread. The healthcare team will use this information—along with the patient’s MRI and pathology findings, tumor biomarkers, overall health and treatment goals—to develop an individualized care plan.

My goal is to find the best treatment. To not overtreat you, and also to not undertreat you.

Sophie Dessureault, MD, PhD

Surgical oncologist, Gastrointestinal Oncology Program

Stage 0 rectal cancer

Stage 0 rectal cancer, also called carcinoma in situ, is confined to the mucosa, the innermost lining of the rectum. The abnormal cells have not crossed the muscularis mucosae, a thin muscle layer beneath the lining, to enter the submucosa. There is no involvement of lymph nodes or distant organs.

Because the abnormal cells remain superficial, treatment is generally local. Depending on the lesion’s size, location and other features, it may be completely removed during a colonoscopy or with a transanal local excision. More extensive surgery is uncommon but may be considered if the lesion cannot be removed completely or the final pathology reveals invasive cancer.

Stage 1 rectal cancer

Stage 1 rectal cancer has grown beyond the innermost lining of the rectum but remains within the rectal wall. A T1 tumor has entered the submucosa, the supportive tissue beneath the mucosa. A T2 tumor has extended into the muscularis propria but has not grown through that muscle into the surrounding fat. Regional lymph nodes and distant organs remain cancer-free.

Surgery is often the primary treatment for stage 1 rectal cancer. A low-risk T1 tumor may be removed through the anus using a local excision technique, helping to preserve the rectum and sphincter. This approach may be considered for a small, accessible tumor that has only superficially invaded the submucosa and shows no evidence of aggressive pathological features or lymph node involvement. 

A tumor with deeper invasion or higher-risk pathological features will usually require removal of the affected portion of the rectum and the surrounding mesorectal tissue. Additional treatment may be recommended if surgery reveals features that increase the likelihood of residual disease or recurrence.

Stage 2 rectal cancer

Stage 2 rectal cancer has grown through the rectal wall or into a nearby structure but has not spread to regional lymph nodes or distant organs. The substage reflects the tumor’s anatomical reach:

• Stage 2A generally describes a tumor that has grown through the muscularis propria into the fat or connective tissue around the rectum.
• Stage 2B describes a tumor that reaches or penetrates the visceral peritoneum, the membrane covering portions of the rectum.
• Stage 2C describes a tumor that directly invades or adheres to a nearby organ or structure, such as the bladder, prostate, uterus or vagina.

Stage 2 rectal cancer is generally considered locally advanced. Treatment often begins before surgery with chemotherapy, radiation therapy or a planned combination of both. Preoperative treatment can shrink the tumor, reduce the risk of local and distant recurrence and improve the chance of removing the cancer with clear margins. Surgery is generally considered afterward, although a carefully selected patient with a complete clinical response may discuss a structured nonoperative surveillance approach with the healthcare team. 

Stage 3 rectal cancer

Stage 3 rectal cancer has spread to regional lymph nodes or has formed certain tumor deposits in nearby tissue, but has not spread to distant organs. The primary tumor may still be relatively limited or may have extended through the rectal wall and into adjacent structures. Stages 3A, 3B and 3C are determined by the combination of tumor depth, the number and location of involved lymph nodes and the presence of qualifying tumor deposits.

Because stage 3 rectal cancer carries a risk of recurrence both within the pelvis and in distant parts of the body, treatment usually combines therapies. Chemotherapy and pelvic radiation therapy are often delivered before surgery, although the exact treatment sequence and need for radiation therapy can vary. Surgery commonly involves total mesorectal excision, which removes the affected portion of the rectum together with the lymph-bearing tissue around it. For a carefully selected patient who has no detectable residual tumor after preoperative treatment, close nonoperative surveillance may be considered at a cancer center with the expertise and resources necessary to perform intensive follow-up.

Stage 4 rectal cancer

Stage 4 rectal cancer has spread beyond the pelvis to a distant site. Common locations include the liver, lungs, distant lymph nodes and peritoneum. Stage 4A generally indicates spread to one distant organ or site, stage 4B indicates spread to more than one distant organ or site and stage 4C indicates spread to the peritoneal surface, with or without metastases elsewhere.

Systemic therapy is central to stage 4 rectal cancer treatment because it can reach cancer cells throughout the body. The regimen may include chemotherapy, targeted therapy or immunotherapy selected based on tumor biomarkers, such as MMR/MSI status and changes in the RAS, BRAF and HER2 genes. Radiation therapy, surgery, ablation or other procedures may be used to relieve symptoms or control specific tumors. If metastases are limited and can be completely treated, the healthcare team may recommend an intensive combination of systemic therapy and surgery or another local treatment with long-term cancer control or cure as the goal.

Prognosis and survival rates for rectal cancer

The prognosis for rectal cancer depends on more than its numbered stage. Other factors that can influence the outcome include the tumor biology, the patient’s response to preoperative therapy and the ability to remove or eliminate all visible cancer.

Rather than using AJCC stages to report survival statistics, the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program uses three broad categories:

• Localized – The cancer has not spread outside the rectum. This category generally includes stage 1 and some stage 2 tumors, but the systems do not align exactly.
• Regional – The cancer has spread to nearby tissues or regional lymph nodes. It can include some stage 2 tumors and most stage 3 cancers.
• Distant – The cancer has metastasized to a distant organ or distant lymph nodes and generally corresponds to stage 4.

The SEER categories are used to report population-level survival statistics and do not replace the AJCC system used to assign an individual patient’s cancer stage. Based on patients diagnosed from 2014 through 2020, the five-year relative survival rate was approximately 90% for localized rectal cancer, 74% for regional rectal cancer and 18% for distant rectal cancer. A five-year relative survival rate compares patients with rectal cancer with people of the same age and sex in the general population. It does not predict how long an individual patient will live. 

It is important to understand that SEER data describes outcomes among large groups of patients treated in previous years. It does not fully reflect treatment advances introduced after those patients were diagnosed. Modern treatment may include more precise surgery and radiation delivery, biomarker-guided targeted therapies and immune checkpoint inhibitors. For example, immunotherapy can produce a durable response in some colorectal cancers with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H), while targeted treatments may be available for tumors with certain BRAF or HER2 alterations. Clinical trials continue to evaluate new ways to improve cure rates, preserve the rectum and control metastatic disease. For these reasons, survival statistics cannot be used to predict an individual outcome.

Frequently asked questions (FAQs) about rectal cancer staging

Understanding how the stage of rectal cancer is assigned can make treatment discussions easier to follow. The following answers address common questions about the rectal cancer staging process:

How do physicians determine the stage of rectal cancer?

Physicians combine the findings from a colonoscopy and biopsy, physical examination, rectal-protocol pelvic MRI and imaging of the chest and abdomen to determine the stage of rectal cancer. Endorectal ultrasound, PET-CT, surgical pathology and other tests may provide additional information in selected situations.

What is the difference between clinical and pathological staging for rectal cancer?

The clinical stage is assigned before treatment using the physical examination, imaging and biopsy findings. It is often marked with a lowercase “c,” as in cT3N1. The pathological stage is based on an examination of tissue removed during surgery. It is marked with a lowercase “p,” and when preoperative treatment has been given, a “y” is added, as in ypT2N0.

How does the depth of the tumor into the rectal wall affect the stage?

Tumor depth determines the T category. Cancer progresses from Tis in the innermost rectal lining to T1 in the submucosa, T2 in the muscular wall, T3 in tissue outside the muscle and T4 at the peritoneal surface or within a nearby organ or structure.

Does the rectal cancer stage change after surgery?

The initial clinical stage is not erased, but surgery may provide a more precise pathological stage and reveal findings that differ from preoperative estimates. If treatment was given before surgery, the post-treatment pathological stage also documents how much cancer remained and helps guide further care.

Can rectal cancer be downstaged with treatment?

Yes. Chemotherapy and radiation therapy given before surgery can shrink a rectal tumor and eliminate cancer from lymph nodes, resulting in a lower post-treatment stage than the initial clinical stage. This response can provide important prognostic information, but the healthcare team will still consider the original stage when planning follow-up and any additional treatment.

What does a complete clinical response mean?

A complete clinical response means that a digital rectal examination (DRE), endoscopy and imaging show no detectable residual tumor after treatment given before surgery. It does not prove that every cancer cell is gone, so a patient who pursues a nonoperative or “watch-and-wait” strategy will need frequent, structured surveillance by a specialized rectal cancer team. 

Is rectal cancer staged differently from colon cancer?

Rectal and colon cancers use the same basic AJCC TNM categories, but the staging workup and treatment implications differ. Pelvic MRI, the tumor’s relationship to the mesorectal fascia and anal sphincter and the possible use of preoperative radiation are particularly important in rectal cancer.

Can recurrent rectal cancer receive a new stage?

A recurrence does not replace the stage assigned at the original diagnosis. Instead, physicians describe where the cancer returned, such as locally in the pelvis or at a distant site, and perform restaging tests to determine its current extent and guide treatment.

The Moffitt Cancer Center difference for rectal cancer staging

Accurate staging is especially important in rectal cancer because small differences in tumor depth, lymph node involvement and the distance between the tumor and surrounding structures can change the recommended sequence of treatment. At Moffitt, radiologists, gastrointestinal pathologists, colorectal surgeons, medical oncologists, radiation oncologists and other specialists collaborate through our Gastrointestinal Oncology Program. Newly diagnosed cases may be reviewed by Moffitt’s specialized Rectal Cancer Tumor Board, allowing the team to evaluate the staging evidence and develop an individualized plan for each patient. 

A patient who comes to Moffitt for an initial evaluation or second opinion may benefit from expert review of biopsy specimens and imaging, including high-resolution pelvic MRI. Molecular analysis can identify tumor features that may affect treatment, eligibility for targeted therapy or immunotherapy and the need for genetic evaluation. When appropriate, the patient may also have opportunities to participate in clinical trials investigating treatment combinations, biomarker-directed therapies and organ-preservation strategies for rectal cancer.

To learn more about rectal cancer staging, you can request an appointment with a specialist in Moffitt’s Gastrointestinal Oncology Program by calling 1-888-663-3488 or submitting a new patient registration form online. We do not require referrals.